| P50 | author | Brian A. Walker | Q40421006 |
| | Frits van Rhee | Q42540710 |
| | Tobias Meißner | Q55979561 |
| | Michael A Bauer | Q57014070 |
| | Cody Ashby | Q58870904 |
| | Gareth J. Morgan | Q61996585 |
| | Faith E Davies | Q88047387 |
| P2093 | author name string | Bart Barlogie | |
| | Erming Tian | |
| | Caleb Stein | |
| | Joshua Epstein | |
| | Niels Weinhold | |
| | Ruslana Tytarenko | |
| | Maurizio Zangari | |
| | Owen W Stephens | |
| | Shayu Deshpande | |
| | Sharmilan Thanendrarajan | |
| | Carolina Schinke | |
| | Christoph J Heuck | |
| | Shweta S Chavan | |
| | Leo Rasche | |
| | Timea Buzder | |
| | Gabor Molnar | |
| | Erich A Peterson | |
| | Purvi H Patel | |
| P2860 | cites work | Initial genome sequencing and analysis of multiple myeloma | Q24629117 |
| | Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells | Q28303091 |
| | Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients | Q34410261 |
| | Curing myeloma at last: defining criteria and providing the evidence | Q34508313 |
| | The molecular classification of multiple myeloma | Q34530992 |
| | Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes | Q34667055 |
| | APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma | Q36055752 |
| | A Big Bang model of human colorectal tumor growth | Q36074227 |
| | Clonal competition with alternating dominance in multiple myeloma. | Q36141846 |
| | Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). | Q36306807 |
| | Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. | Q36370851 |
| | Clinical value of molecular subtyping multiple myeloma using gene expression profiling | Q36540781 |
| | Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations | Q36622188 |
| | Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. | Q36812163 |
| | A comprehensive survey of the mutagenic impact of common cancer cytotoxics | Q36886849 |
| | Heterogeneity of genomic evolution and mutational profiles in multiple myeloma | Q37528285 |
| | Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms | Q37564751 |
| | The genetic architecture of multiple myeloma | Q37718836 |
| | Double-hit B-cell lymphomas | Q37813897 |
| | The genetic architecture of multiple myeloma. | Q38001913 |
| | SomaticSignatures: inferring mutational signatures from single-nucleotide variants. | Q39769410 |
| | Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. | Q40231918 |
| | Analysis of PTEN deletions and mutations in multiple myeloma | Q40383211 |
| | Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. | Q40633414 |
| | Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease | Q40742165 |
| | APOBEC3 proteins and genomic stability: the high cost of a good defense | Q40848214 |
| | PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors | Q41197854 |
| | Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia | Q41296537 |
| | Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. | Q41766580 |
| | Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma | Q42923836 |
| | Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy | Q43024864 |
| | A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. | Q53246749 |
| | Hypodiploidy is a major prognostic factor in multiple myeloma | Q74541841 |
| | Multiple myeloma | Q86407303 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1735-1744 | |
| P577 | publication date | 2016-08-11 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma | |
| P478 | volume | 128 | |